Stock comparison
Halozyme Therapeutics
Organon &
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
OGN
Organon &
Market cap
$3.53B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HALO | OGN | Winner |
|---|---|---|---|
| Warren Buffett | 79B | 57C | HALO |
| Benjamin Graham | 83A | 78B | HALO |
| Philip Fisher | 65B | 38D | HALO |
| Peter Lynch | 53D | 27F | HALO |
| Joel Greenblatt | 40D | 21F | HALO |
| Charlie Munger | 80C | 48D | HALO |
| Terry Smith | 84A | 46D | HALO |
Side-by-side metrics
| Metric | HALO | OGN |
|---|---|---|
| Market cap | $8.1B | $3.53B |
| P/E (TTM) | 24.0x | 14.2x |
| EV/EBIT | 10.2x | 8.5x |
| ROIC (TTM) | 23.65% | 5.16% |
| Gross margin | 81.24% | 53.11% |
| Net margin | 23.13% | 3.99% |
| Revenue CAGR 5y | 33.23% | -0.35% |
| EPS CAGR 5y | -1.98% | -39.38% |
| Debt / Equity | 1.0x | 9.5x |
| Dividend yield | 0.0% | 0.6% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HALO leads on
- Revenue CAGR 5y33.23%vs -0.35%+101%
- EPS CAGR 5y-1.98%vs -39.38%+95%
- Debt / Equity1.0xvs 9.5x+90%
- Net margin23.13%vs 3.99%+83%
OGN leads on
- Dividend yield0.6%vs 0.0%+100%
- P/E (TTM)14.2xvs 24.0x+41%
- EV/EBIT8.5xvs 10.2x+16%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.